E Radecka1, M Magnusson, A Magnusson. 1. Department of Radiology, University Hospital of Uppsala, Sweden. eva.radecka@akademiska.se
Abstract
PURPOSE: To assess patient mortality and survival time, period of catheterization, and indications for percutaneous nephrostomy (PCN) withdrawal in patients treated with PCN for urinary obstruction due to malignancy. MATERIAL AND METHODS: A retrospective analysis of 151 patients treated with 257 PCNs in a 5-year period was performed. Data on survival time, duration of catheterization, and clinical end-points for PCN treatment were collected. RESULTS: The median survival time of the patients was 255 days, while median catheterization time was 62 days. The majority of patients (84) died with the catheter. Indications for PCN withdrawal were surgery, stent treatment, catheter displacement, and response to medical treatment. CONCLUSION: The majority of patients with malignancy treated with PCN have advanced disease and short life expectancy. Factors such as diagnosis, prognosis, economy, and the patient's preference influence the choice of urinary diversion method. However, PCN should be considered in patients with malignancy on grounds of safety and low cost.
PURPOSE: To assess patient mortality and survival time, period of catheterization, and indications for percutaneous nephrostomy (PCN) withdrawal in patients treated with PCN for urinary obstruction due to malignancy. MATERIAL AND METHODS: A retrospective analysis of 151 patients treated with 257 PCNs in a 5-year period was performed. Data on survival time, duration of catheterization, and clinical end-points for PCN treatment were collected. RESULTS: The median survival time of the patients was 255 days, while median catheterization time was 62 days. The majority of patients (84) died with the catheter. Indications for PCN withdrawal were surgery, stent treatment, catheter displacement, and response to medical treatment. CONCLUSION: The majority of patients with malignancy treated with PCN have advanced disease and short life expectancy. Factors such as diagnosis, prognosis, economy, and the patient's preference influence the choice of urinary diversion method. However, PCN should be considered in patients with malignancy on grounds of safety and low cost.
Authors: Sang Hoon Song; Sahyun Pak; In Gab Jeong; Kun Suk Kim; Hyung Keun Park; Choung-Soo Kim; Hanjong Ahn; Bumsik Hong Journal: Int Urol Nephrol Date: 2014-10-15 Impact factor: 2.370
Authors: Benjamin A Spencer; Beverly J Insel; Dawn L Hershman; Mitchell C Benson; Alfred I Neugut Journal: Support Care Cancer Date: 2013-01-06 Impact factor: 3.603
Authors: Iftikhar Ahmad; Mudassar Saeed Pansota; Muhammad Tariq; Muhammad Shahzad Saleem; Shafqat Ali Tabassum; Akbar Hussain Journal: Pak J Med Sci Date: 2013-05 Impact factor: 1.088
Authors: Rabea Ahmed Gadelkareem; Ahmed Mahmoud Abdelraouf; Ahmed Mohammed El-Taher; Abdelfattah Ibrahim Ahmed; Nasreldin Mohammed Journal: Int Urol Nephrol Date: 2022-07-06 Impact factor: 2.266